Targeted EGFR Inhibitors and Immuno-Oncology Regimens Redefining Head and Neck Cancer Survival
Advancing systemic treatment choices through targeted biologics and immune checkpoint inhibitors is improving survival rates across advanced head and neck squamous cell carcinomas (HNSCC). Detailed analysis within the Head and Neck Cancer Market report demonstrates how anti-PD-1 immunotherapies (such as pembrolizumab and nivolumab) paired with targeted anti-EGFR monoclonal antibodies...
0 Comments 0 Shares 159 Views 0 Reviews